In a significant step toward addressing the dire opioid crisis, researchers at MIT and Brigham and Women’s Hospital have designed an innovative implantable device intended to swiftly counteract opioid overdoses. As reported by MIT News, the device, roughly the dimensions of a stick of gum, is deployed under the skin to monitor vital signs and administer a dose of naloxone once it detects an overdose situation.
With the opioid epidemic claiming over 100,000 lives in 2023, the need for effective interventions is critical. This device aims to eliminate delays that can mean the difference between life and death. It detects an imminent overdose by monitoring heart rate, breathing rate, and other vital signs, then quickly administers naloxone, an opioid antidote. This development could save many lives, as opioid overdoses can happen so quickly that traditional emergency responses are often too slow to prevent death.
The device's capabilities were showcased in animal studies, where it demonstrated a 96 percent success rate in reversing overdose effects, according to the researchers' paper in the journal Device. Giovanni Traverso, an associate professor at MIT and senior author of the study, expressed that they primarily focus on the high-risk population to address a significant unmet need in the population that suffers from substance abuse and opiate dependency.
Comprised of a team including Hen-Wei Huang, Peter Chai, SeungHo Lee, Tom Kerssemakers, Ali Imani, and Jack Chen, the researchers have taken a multidisciplinary approach to combat the opioid crisis. According to a statement obtained by MIT News, Huang highlights the challenge in developing an engineering solution to prevent overdoses—aiming to ensure patient adherence, reduce stigma, and quickly deliver antidotes. The device represents a critical intersection of technology, medicine, and patient care.
The researchers see high-risk individuals, such as those who have previously overdosed, as the main users of this life-saving technology. The next steps involve making the device easier to use, improving its battery life, currently about two weeks, and testing it on humans within the next three to five years. Peter Chai highlighted the device's potential to be part of a broader harm-reduction strategy, efficiently delivering naloxone to prevent death from opioid overdose and providing the opportunity to support individuals with opioid use disorder. This project has received funding from Novo Nordisk, the McGraw Family Foundation at Brigham and Women’s Hospital, and the MIT Department of Mechanical Engineering.
